Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):545–548. doi: 10.1128/aac.39.2.545

Aminoglycoside dosing weight correction factors for patients of various body sizes.

A M Traynor 1, A N Nafziger 1, J S Bertino Jr 1
PMCID: PMC162577  PMID: 7726530

Abstract

Prior investigations have suggested the use of a dosing weight correction factor of ideal body weight (IBW) plus 40% excess body weight (EBW, where EBW = total body weight [TBW] - IBW) to determine the weight to use for aminoglycoside dosing in morbidly obese (TBW/IBW ratio, > 2) patients. Little data are available to provide dosing information for underweight or moderately obese patients. We investigated aminoglycoside pharmacokinetics in 1,708 patients receiving gentamicin and tobramycin. Patients were stratified into underaverage-weight or overweight weight categories based on both TBW/IBW ratio and body mass index (weight/height2 ratio), which has been shown to correlate with physiologic estimates of body fat. Regression analyses revealed that the TBW/IBW ratio predicts the volume of distribution. Dosing weight correction factors to give equivalent predicted peak aminoglycoside concentrations with a 2-mg/kg loading dose are 1.13 times the TBW for underweight patients and 0.43 times the EBW plus IBW for overweight patients. There were no large differences between the dosing weight correction factors derived from IBW- and body mass index-based classification systems. These data generate useful aminoglycoside dosing weight equations for both underweight and overweight patients.

Full Text

The Full Text of this article is available as a PDF (170.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer L. A., Blouin R. A., Griffen W. O., Jr, Record K. E., Bell R. M. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm. 1980 Apr;37(4):519–522. [PubMed] [Google Scholar]
  2. Bauer L. A., Edwards W. A., Dellinger E. P., Simonowitz D. A. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–647. doi: 10.1007/BF00542215. [DOI] [PubMed] [Google Scholar]
  3. Bertino J. S., Jr, Booker L. A., Franck P. A., Jenkins P. L., Franck K. R., Nafziger A. N. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993 Jan;167(1):173–179. doi: 10.1093/infdis/167.1.173. [DOI] [PubMed] [Google Scholar]
  4. Bertino J. S., Jr, Booker L. A., Franck P., Rybicki B. Gentamicin pharmacokinetics in patients with malignancies. Antimicrob Agents Chemother. 1991 Jul;35(7):1501–1503. doi: 10.1128/aac.35.7.1501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blouin R. A., Mann H. J., Griffen W. O., Jr, Bauer L. A., Record K. E. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther. 1979 Oct;26(4):508–512. doi: 10.1002/cpt1979264508. [DOI] [PubMed] [Google Scholar]
  6. Bravo M. E., Arancibia A., Jarpa S., Carpentier P. M., Jahn A. N. Pharmacokinetics of gentamicin in malnourished infants. Eur J Clin Pharmacol. 1982;21(6):499–504. doi: 10.1007/BF00542045. [DOI] [PubMed] [Google Scholar]
  7. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  8. Deziel-Evans L. M., Murphy J. E., Job M. L. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986 Apr;5(4):319–324. [PubMed] [Google Scholar]
  9. Etzel J. V., Nafziger A. N., Bertino J. S., Jr Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother. 1992 Mar;36(3):679–681. doi: 10.1128/aac.36.3.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Forbes G. B., Welle S. L. Lean body mass in obesity. Int J Obes. 1983;7(2):99–107. [PubMed] [Google Scholar]
  11. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet. 1989;17 (Suppl 1):68–88. doi: 10.2165/00003088-198900171-00006. [DOI] [PubMed] [Google Scholar]
  12. Levy R. H., Bauer L. A. Basic pharmacokinetics. Ther Drug Monit. 1986;8(1):47–58. doi: 10.1097/00007691-198603000-00010. [DOI] [PubMed] [Google Scholar]
  13. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  14. Moore R. D., Smith C. R., Lietman P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. doi: 10.1016/0002-9343(84)90358-9. [DOI] [PubMed] [Google Scholar]
  15. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  16. Revicki D. A., Israel R. G. Relationship between body mass indices and measures of body adiposity. Am J Public Health. 1986 Aug;76(8):992–994. doi: 10.2105/ajph.76.8.992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sawchuk R. J., Zaske D. E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976 Apr;4(2):183–195. doi: 10.1007/BF01086153. [DOI] [PubMed] [Google Scholar]
  18. Schwartz S. N., Pazin G. J., Lyon J. A., Ho M., Pasculle A. W. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978 Oct;138(4):499–505. doi: 10.1093/infdis/138.4.499. [DOI] [PubMed] [Google Scholar]
  19. Sketris I., Lesar T., Zaske D. E., Cipolle R. J. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol. 1981 Jul;21(7):288–293. doi: 10.1002/j.1552-4604.1981.tb01769.x. [DOI] [PubMed] [Google Scholar]
  20. Tointon M. M., Job M. L., Peltier T. T., Murphy J. E., Ward E. S. Alterations in aminoglycoside volume of distribution in patients below ideal body weight. Clin Pharm. 1987 Feb;6(2):160–162. [PubMed] [Google Scholar]
  21. Williamson D. F., Kahn H. S., Remington P. L., Anda R. F. The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med. 1990 Mar;150(3):665–672. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES